Following people with sickle cell disease as they move into adulthood
Observes people with sickle cell disease over time, including through adulthood, to study organ changes.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Baton Rouge, Charlotte, Memphis, and Peoria, United StatesSee the 6 sites
- Trial code
- Registry title
- Sickle Cell Clinical Research and Intervention Program
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 15 Apr 2014
- Expected to end
- Dec 2044
- Type of study
- Observational
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with sickle cell disease of any genotype. It follows them at regular clinic visits. Some can also join a hydroxyurea blood-level sub-study.
- Sex
- Everyone can join, any sex.
- Disease stage
- Sickle cell disease of any genotype.
- Earlier treatment
- Only for the hydroxyurea (HU) sub-study: currently taking HU, at the maximum tolerated dose for at least 90 days before joining.
Main reasons for not taking part
- Any medical or social reason that the principal investigators think makes taking part ill-advised.
- Sub-study: cannot complete the blood draws needed for the PK sampling.
- Sub-study: the participant or legal guardian cannot or will not give written informed consent.
The registry criteria, word for word
Show all 5 criteriaShow less
Other criteria
- SCCRIP Inclusion Criteria:
- A diagnosis of sickle cell disease of any genotype
- PK Sub-study Inclusion Criteria:; Participants at St. Jude Children's Research Hospital who are consented to the parent protocol (SCCRIP, Amendment 6.1 or above); Participants currently completing a hydroxyurea (HU) regimen, who have achieved maximum tolerated dose and have maintained that dose for a minimum of 90 days prior to enrollment; SCCRIP Exclusion Criteria:
- Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
- PK Sub-study Exclusion Criteria:; Participants unable to complete the blood draws required for PK sampling; Inability or unwillingness of research participant or legal guardian/representative to give written informed consent; Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
Where in United States
- Our Lady of the Lake Regional Medical CenterBaton Rouge, United StatesContact: Deepa Manwani, MDNo longer taking part
- Novant Health - Hemby Children's HospitalCharlotte, United StatesContact: Felipe Bautista Otanez, MDTaking people
- Methodist Adult Comprehensive Sickle Cell CenterMemphis, United StatesContact: Marquita D. Nelson, MDTaking people
- Regional One Health, Diggs-Kraus Sickle Cell CenterMemphis, United StatesContact: Ugochi Ogu, MDTaking people
- St. Jude Children's Research HospitalMemphis, United StatesContact: Deepa Manwani, MDTaking people
- Children's Hospital of Illinois at OSF-Saint Francis Medical CenterPeoria, United StatesContact: Kay Saving, MDTaking people
About the trial
What the trial wants to find out
Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such as hydroxyurea, in preventing organ dysfunction later in life is not clear. Extended follow-up of patients through the transition into adulthood is imperative to understand the long-term implications of pediatric sickle cell care.
Read full original descriptionShow less
This observational study will collect data in a systematic fashion at participants' regular clinic visits (in-person or remote) to answer the objectives described below.
In addition to primary study objectives, SCCRIP participants will be eligible to participate in a sub-study, which will investigate genetically determined responses to Hydroxyurea (HU) via a pharmacokinetic study (PK). This one time study will involve blood collection at timed intervals proceeding a dose of HU. Defining the basis for this inter-individual variability will allow the identification of poor HU responders prior to initiation of therapy and the seeking of alternative treatments which seek to optimize disease treatment by accounting for individual variability in genes, environment, and lifestyle.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sickle Cell Clinical Research and Intervention Program
- Plain-language title
- Following people with sickle cell disease as they move into adulthoodGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia-Associated Kidney Function.American journal of hematology, 2026
- Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.American journal of hematology, 2025
- Machine learning to optimize automated RH genotyping using whole-exome sequencing data.Blood advances, 2024
- Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.American journal of hematology, 2023
- Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.Experimental biology and medicine (Maywood, N.J.), 2021
- Record updated
- 4 June 2026